These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16278465)

  • 1. The changing face of prostate cancer.
    Cooperberg MR; Moul JW; Carroll PR
    J Clin Oncol; 2005 Nov; 23(32):8146-51. PubMed ID: 16278465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New aspects in prostate cancer therapy].
    Dvorácek J
    Cas Lek Cesk; 2007; 146(10):736-45. PubMed ID: 18020004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer: epidemiology and health-related quality of life.
    Penson DF; Rossignol M; Sartor AO; Scardino PT; Abenhaim LL
    Urology; 2008 Dec; 72(6 Suppl):S3-11. PubMed ID: 19095126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
    Hegarty JM; Wallace M; Comber H
    Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
    Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of localized prostate cancer in men over 65 years.
    Cooperberg MR; Konety BR
    Curr Opin Urol; 2009 May; 19(3):309-14. PubMed ID: 19357512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional treatments of localized prostate cancer.
    Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
    Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
    Leibovici D; Lindner A; Stay K; Zisman A
    Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and follow-up strategies for patients on active surveillance.
    Dall'Era MA; Carroll PR
    Curr Opin Urol; 2009 May; 19(3):258-62. PubMed ID: 19295434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
    Peters CA; Stock RG; Blacksburg SR; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):24-9. PubMed ID: 18692325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
    J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High risk prostate cancer: evolving definition and approach to management.
    Chughtai B; Mian BM
    Can J Urol; 2008 Dec; 15(6):4375-80. PubMed ID: 19046490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
    Dall'Era MA; Konety BR
    Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.